GMAB and 0MGB Related Headlines
Go Back- Genmab Publishes 2025 Annual Report
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
- Genmab Portfolio Prioritization Update
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Genmab Announces Financial Results for the Nine Months of 2025
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
- Genmab agrees to acquire Merus for $8 billion in all-cash deal
- Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
- Major Shareholder Announcement
- Genmab Announces Financial Results for the First Half of 2025
- Genmab phase 3 trial meets endpoints for follicular lymphoma treatment
- Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
GMAB and 0MGB Related Press Releases
Go Back- Genmab Publishes 2025 Annual Report
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
- Genmab Portfolio Prioritization Update
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Genmab Announces Financial Results for the Nine Months of 2025
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
- Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
- Major Shareholder Announcement
- Genmab Announces Financial Results for the First Half of 2025
- Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
